Linking Ubiquitin Research to Drug Discovery


Ubiquigent Limited is focused on enabling and supporting ubiquitin system drug discovery. Our biology and chemistry platforms allow us to design and develop novel compounds targeted towards ubiquitin system proteins as well as evaluate those of our partners.

Ubiquigent provides support to programmes at all stages from the provision of Research Tools and reagents to assay development compound profiling Drug Discovery Services through to larger Collaborative Drug Discovery Programmes for the delivery of hit and lead compounds.  At every stage Ubiquigent leverages its ubiquitin system focused knowledge and expertise to support is partners programmes.

The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.

Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The Company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.

Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the Company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.